Skip to main content

Table 5 Multivariate analysis of hazard ratio of OS with trastuzumab discontinuation

From: Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

Variable

Adjusted Hazard Ratio

Std. Err.

95% CI

P-value

Discontinuation Trastuzumab

4.76

1.59

2.47–9.16

< 0.001

Age

0.99

0.01

0.97–1.01

0.302

Stage, 1 or 2 vs Stage 3

2.45

0.74

1.36–4.41

0.003

Grade, 1 or 2 vs Grade 3

1.69

0.53

0.91–3.14

0.094

ER status, Negative vs Positive

0.64

0.20

0.34–1.20

0.163

Cardiomyopathy Yes vs No

0.31

0.13

0.14–0.70

0.004